A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This 2 arm study will compare the efficacy and safety of monthly administration of
subcutaneous Mircera versus epoetin alfa for the maintenance of hemoglobin levels in dialysis
patients with chronic renal anemia. Patients currently receiving maintenance treatment with
epoetin alfa will be randomized to receive either monthly injections of Mircera with a
starting dose (120, 200 or 360 micrograms) derived from the dose of epoetin alfa they were
receiving in the week preceding study start, or to continue on epoetin alfa treatment. The
anticipated time on study treatment is 3-12 months, and the target sample size is 100-500
individuals.